Coherus Biosciences | CHRS - Assets


Coherus Biosciences reported $191.18M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amarin USD 624.36M 21.4M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Baxter International USD 19.79B 55M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Fujifilm JPY 6.05T 170.69B Mar/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Merck USD 129.8B 1.12B Jun/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Teva Pharmaceutical Industries USD 39.86B 183M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026
Zoetis USD 15.08B 77M Jun/2026